Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IndiBlade bladder-sparing immunotherapy plus chemoradiotherapy study
NL-OMON52087Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ipilimumab, nivolumab, mitomycin c, fluorouracil and capecitabine in transitional cell carcinoma of the bladder (TCC) and bladder cancer, sponsored by Netherlands Cancer Institute. Started Mar 2022; status: recruiting.
02
Drugs
03
Conditions
transitional cell carcinoma of the bladder (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON52087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52087.